Polymerase and Biosynthesis

renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in combination with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma. Side effects of drugs and complications in the use of drugs: hematoma (epidural, spinal, after angiography, retroperitoneal, intracranial), hypersensitivity reactions, local or general AR; of here hematomas using эnoksaparyna against the background of epidural or spinal anesthesia in some cases can lead to neurological disorders of varying degrees of neurological damage, including - to the formation of long-term or permanent paralysis (risk increases with concurrent use of drugs affecting hemostasis), thrombocytopenia (mild, transient, asymptomatic thrombocytopenia in the first days of therapy, possible imunoalerhichna thrombocytopenia with thrombosis that in some cases complicated myocardial ischemia organ or limb, with long-term treatment (more than 5 weeks) the possible early development of osteoporosis, increase the level of liver enzymes, injection site reactions to the drug (from mild irritation to pain, bruising and hematomas at injection site in exceptional cases - skin necrosis, skin rashes or bullous systemic AR, including anaphylactoid), thrombocytosis, anemia, clotting disorder, hyperlipidemia, spontaneous rupture of the spleen. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml what anti-Xa IU) or 0.8 ml (8000 anti-Xa IU). Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or Post-Menopausal Bleeding patients with hemofiltratsiyi h. Heparin group. The main pharmaco-therapeutic effects: Antithrombotic. Indications for use drugs: prevention of venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including what fractures (including prolonged what operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI with ST what rise to prevent deaths, re-MI patients who are treated Thrombolytic or in those who what did not receive other what of reperfusion therapy. The main pharmaco-therapeutic effects: Antithrombotic, protyzhortalna. or hr.